Heat Biologics Sees Positive Data From Lung-Cancer-Treatment Trial
February 09 2021 - 8:44AM
Dow Jones News
By Chris Wack
Heat Biologics Inc. said it saw positive interim data of its
Phase 2 trial of HS-110 in combination with Bristol-Myers Squibb's
Opdivo nivolumab in advanced non-small cell lung cancer.
The company's HS-110 is an "off-the-shelf" allogeneic cell-based
therapy designed to activate patients' immune system against
multiple cancer testis antigens to elicit a diverse and robust
immune response against tumor cells.
Heat Biologics said substantial survival benefit was observed in
a cohort of previously treated, checkpoint inhibitor naive patients
with advanced non-small cell lung cancer.
A median progression free survival of 1.8 months and a median
overall survival of 24.6 months was observed with a median
follow-up time of 19.4 months. The one-year survival rate of cohort
A is 61.7%.
For NSCLC patients who had previously been treated with a
checkpoint inhibitor and whose disease had subsequently progressed,
a median progression free survival of 2.8 months and median overall
survival of 11.9 months was observed with a median follow-up time
of 11.9 months.
The company said 30% of the patients in Cohort A and 26% of the
patients in Cohort B are still alive. HS-110 has a favorable safety
profile and has been administered in 200 patients to date. There
have been no treatment-related serious adverse reactions. A review
of immune-related adverse events reported in the study raised no
safety concerns.
Heat Biologics shares were up 49%, to $12.48, in premarket
trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 09, 2021 08:29 ET (13:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024